Understand how low libido differs from erectile dysfunction, why clinicians assess both, and where testosterone testing and cardiovascular risk fit.
Low libido concerns sexual desire, while erectile dysfunction concerns erection quality, and separating them helps clinicians assess hormonal symptoms alongside other health risks.
This article is for informational purposes and is not medical advice. Changes in sexual function and decisions about testing belong in an assessment with a qualified clinician.
Libido means sexual desire. When desire has changed, the clinical question concerns interest in sex rather than how firm an erection becomes. Describing everything as a sexual problem leaves those separate questions combined. Naming the change more precisely gives the clinical discussion a clearer starting point.
The European Association of Urology (EAU) recommends asking about desire separately from erection rigidity and duration. Its sexual-health history also distinguishes arousal from ejaculation and orgasm. These are related parts of sexual function, but the guideline does not treat them as interchangeable descriptions.
The distinction also helps when desire is not the main concern. If the issue is arousal, ejaculation or orgasm, those terms identify a different part of the history. The EAU's approach gives each topic its own place. It does not require every sexual concern to be described through the language of erections.
The EAU recommends screening men with erectile dysfunction for symptoms of possible hypogonadism. These include decreased libido, low energy and fatigue. That makes a change in desire relevant to the hormonal part of an assessment even when an erection problem brought the man to the appointment.
The clinical role of low libido here is as a symptom to describe. It is not a direct measurement of testosterone. Separating the symptom from the test helps keep the discussion focused on what has changed before considering what that change might mean.
For readers trying to name the concern, Testostra's discussion of changes in sexual interest provides related context. The useful distinction is between describing desire and deciding on its cause. The first helps inform the clinical conversation; the second requires assessment.
Erectile dysfunction (ED) concerns difficulty with erection firmness or with maintaining an erection. Unlike libido, this describes erectile performance rather than sexual interest. The mechanical distinction is straightforward: desire concerns interest in sex; rigidity and duration concern the erection itself.
The EAU recommends asking separately about erection rigidity and duration. It also includes morning erections in the sexual-health history. This means that a useful description of an erection concern can be more specific than saying that sexual function has become worse.
Firmness and duration deserve separate attention because the guideline asks about both. A description focused only on whether an erection occurs leaves out how firm it is and whether it lasts. Morning erections are another feature to describe rather than fold into a general statement about desire.
This is why a clinician's questions about morning erections and erection duration are not simply another way to ask about sex drive. They add detail about erectile function. Answering one question does not make the other unnecessary, and mentioning desire does not replace a description of firmness or maintenance.
The EAU states that ED is associated with increased cardiovascular risk and should be considered a possible precursor of cardiovascular disease. This gives erection concerns medical relevance beyond the question of testosterone. Its guidance places cardiovascular risk alongside hormonal assessment rather than replacing one with the other.
That broader framing matters when the discussion starts with an assumption about hormones. A clinical assessment has room for both the erection symptoms and the wider health questions raised by the guideline. It does not need to choose one topic before hearing the other.
Testostra's overview of the evaluation of erection difficulties offers further context for that wider conversation. The central point here is to describe erection quality directly so it receives attention as a distinct concern.
Separating low libido from ED does not mean creating unrelated categories. The EAU explicitly brings them together by recommending assessment of desire and screening for possible hypogonadism symptoms in men with ED. The distinction helps organise the evaluation rather than divide it.
The EAU recommends early-morning, fasting total testosterone as part of hormonal testing in an ED assessment. This is a recommendation about the timing and conditions of a laboratory measurement within clinical evaluation. It sits alongside the sexual-health history rather than standing in for it.
The history describes the concern: reduced desire or a change in erection firmness or duration. The laboratory test measures total testosterone. Keeping these roles separate makes it easier to understand why a clinician asks detailed symptom questions even when a blood test is being considered.
For example, a concern described mainly as reduced interest calls for a clear account of desire. A concern described mainly as reduced firmness calls for a clear account of erection quality. When both have changed, both belong in the history rather than being compressed into a presumed hormone problem.
Testostra's article on considering low testosterone and erection problems together adds context to this distinction. The practical aim is not to pick a hormonal explanation in advance. It is to make the symptom description clear enough for the clinician to assess it.
In its September 2026 statement, the Endocrine Society said evidence is insufficient to support population-level screening of asymptomatic men for hypogonadism. The statement addressed a Defense Health Agency testosterone-deficiency guideline. It reiterated that the Society's own clinical practice guideline does not support population-level screening in men without symptoms.
This differs from the EAU's recommendation to include hormonal testing in an ED assessment. One concerns testing a population without symptoms; the other concerns evaluation of a sexual-health complaint. Treating them as the same question would blur the distinction between general screening and symptom-led clinical care.
Age alone therefore should not substitute for a discussion of symptoms. Equally, a caution about population-wide screening is not a statement that testosterone testing is never appropriate. The question is what the test contributes to the clinical assessment being considered.
Neither low libido nor ED alone establishes hypogonadism. The cardiovascular association described by the EAU does not mean that a man with ED necessarily has cardiovascular disease.
It can help to separate the description from the explanation in the conversation. Reduced desire names a symptom category, while low testosterone proposes a cause. Reduced firmness names an erection concern, while a claim about cardiovascular disease goes beyond the symptom itself. Keeping those levels distinct lets the evaluation address the complaint without treating the opening description as a conclusion.
The practical next step is a clearer description for a qualified clinician rather than a diagnosis drawn from one symptom. The EAU's history-taking categories support discussing the following points separately:
These are topics for a conversation, not a scoring tool or a self-test for low testosterone. Describing more than one change is appropriate when more than one aspect is affected. There is no need to force the concern into a single label before the appointment.
Low libido and ED are best viewed as distinct parts of sexual health that clinicians assess together, with hormonal findings and cardiovascular risk kept in context.
Desire changes and erection difficulties raise different questions, while concern about testosterone can blur the distinction. Testostra addresses uncertainty about symptoms and their possible causes through evidence-led explanations of male hormonal health, giving readers clearer language for discussing concerns with a clinician without assigning a diagnosis or directing personal treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra